Intel Corporation (INTC) Q3 2026: Revenue Growth Amid Mixed Earnings — Cautiously Optimistic: Slides 25.8% at Open — Post-Earnings Analysis
QuoteReporter

Intel Corporation reported its third-quarter 2026 financial results, revealing a notable increase in revenue but a decline in earnings per share (EPS) compared to the previous year. Specifically, revenue reached $16.5 billion, reflecting a growth of $2.8 billion or +21% year-over-year (YoY). However, net income attributable to Intel decreased to $3.3 billion, down $0.8 billion or -18% YoY, and GAAP EPS fell to $0.60, down $0.30 or -33% YoY.
This quarter presents a mixed bag for shareholders. While the revenue growth is a positive indicator of demand and operational execution, the significant drop in earnings raises concerns about profitability and cost management. The decline in EPS, despite increased revenue, suggests that Intel is facing challenges in maintaining margins, particularly in its Client Computing and Physical AI Group, which saw a 5% decline in revenue.
Key Financial Metrics:
- Revenue: $16.5 billion, up 21% YoY from $13.7 billion.
- Net Income: $3.3 billion, down 18% YoY from $4.1 billion.
- GAAP EPS: $0.60, down 33% YoY from $0.90.
- Non-GAAP EPS: $0.52, up 126% YoY from $0.23.
- Gross Margin: 43.0%, up 4.8 percentage points from 38.2%.
- Operating Margin: 15.3%, up 10.3 percentage points from 5.0%.
Dividend and Share Buyback:
Intel did not announce any changes to its dividend or share buyback programs in this release, which may be a point of interest for investors looking for returns beyond capital appreciation.
Guidance for Q4 2026:
Looking ahead, Intel forecasts fourth-quarter revenue between $15.0 billion and $16.0 billion and expects GAAP EPS of $0.10 and non-GAAP EPS of $0.25. This guidance indicates a potential slowdown in revenue growth, as it suggests a decrease from the current quarter's performance.
Analyst Perspective:
The results indicate that while Intel is successfully growing its top line, the challenges in profitability and margin management could weigh on investor sentiment. The significant growth in the Data Center and AI segment, which saw a 78% increase in revenue, is a bright spot and reflects the company's strategic focus on high-demand areas. However, the ongoing slowdown in the PC market, as noted by management, could hinder future growth prospects.
Forward-Looking Catalysts:
Investors should closely monitor Intel's ability to navigate the current PC industry headwinds and its execution on expanding supply for its Xeon family products. Additionally, the company's collaborations, such as the multiyear partnership with Oracle and the acquisition of Classiq, could provide future growth avenues. The upcoming earnings call will likely provide further insights into management's strategies to enhance profitability and manage costs effectively.
In summary, while Intel's revenue growth is commendable, the decline in earnings and cautious guidance for the next quarter suggest that shareholders should remain vigilant as the company navigates a challenging market landscape.
Consolidated Condensed Statements of Operations and Other Information (In Millions, Except Per Share Amounts; Unaudited)
Consolidated Condensed Balance Sheets (In Millions, Except Par Value; Unaudited)
Quarterly Earnings — Revenue vs. Estimate
| Quarter Label | Quarter End | Rev Actual ($M) | Rev Est ($M) | Rev Var ($M) | EPS Actual | EPS Est | EPS Beat |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 2026-10 | 16,510 | 16,560 | -50 | 0.52 | 0.41 | +0.11 |
| Q2 2026 | 2026-06-30 | 16,130 | 14,430 | +1,700 | 0.42 | 0.21 | +0.21 |
| Q1 2026 | 2026-03-31 | 13,580 | 12,320 | +1,260 | 0.29 | 0.01 | +0.28 |
| Q4 2025 | 2025-12-31 | 13,670 | 13,370 | +300 | 0.15 | 0.08 | +0.07 |
| Q3 2025 | 2025-09-30 | 13,650 | 13,100 | +550 | 0.23 | 0.00 | +0.23 |
Revenue vs. Estimate — 5 Quarters
EPS vs. Estimate — 5 Quarters
Technical Analysis — 90-Day Price Chart
Intel Corporation (INTC) is trading at $66.14, well below its short- and medium-term moving averages—SMA20 ($96.41), SMA50 ($101.11)—confirming a strong downtrend. The lack of bullish crossovers suggests persistent weakness. With an RSI(14) of 23.0, the stock is deeply oversold, though no clear reversal signal has emerged. Recent volume of 213.7M shares nearly doubled the 20-day average of 103.8M, indicating elevated selling pressure. The stock is near its 52-week low of $64.12, just 3.1% above that level, reinforcing downside risks. The wide gap from its 52-week high ($142.35) underscores weak momentum and leaves minimal overhead resistance. Unless buyers step in near the lower boundary, further downside toward the $64.12 support remains likely. The technical setup remains bearish absent a significant catalyst.
Related Articles

Starbucks Corporation (SBUX) Q4 2026: Calm Open (+0.2%) — Post-Earnings Analysis
EARNINGS DAY PRICE ACTION — SBUXCalm Open (+0.19%)Prev close $105.51 → Open $105.71 — then slid 3.19% intraday Quarterly Earnings — Revenue vs. Estimate Quarter Label Quarter End Rev Actual ($M) Rev Est ($M) Rev Var ($M) EPS Actual…

Gilead Sciences (GILD) Q3 2026: Revenue Growth Amid Mixed Earnings — Cautiously Optimistic: Gaps +2.6% at Open — Post-Earnings Analysis
EARNINGS DAY PRICE ACTION — GILDGapped Up +2.65%Prev close $165.61 → Open $170.00 — then rallied 1.39% intraday Gilead Sciences, Inc. (Nasdaq: GILD) reported its third-quarter 2026 financial results, revealing a total product sales increase of $1.0 billion or +13% year-…

Regeneron Pharmaceuticals (REGN) REGN Q3 Financial Results Summary
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026: Strong Revenue Growth and Record Sales — Positive Outlook Regeneron Pharmaceuticals, Inc. (REGN) reported a robust performance in the third quarter of 2026, with total revenues increasing by $1.4 billion or +36% year-over-year, reaching $5.1 billion...